Skip to main content
You have permission to edit this article.
FDA inspection finds most problems resolved at nation’s only anthrax vaccine maker

FDA inspection finds most problems resolved at nation’s only anthrax vaccine maker


LANSING, Mich. (AP) – The nation’s only manufacturer of an anthrax vaccine on Thursday expressed confidence it will soon win federal approval to distribute the vaccine.


On the Net: BioPort Corp

U.S. Dept of Health and Human Services

Food and Drug Administration, which spent the last week inspecting BioPort Corp.’s labs, said Wednesday that the company had satisfactorily addressed most of the procedures it wanted to see fixed before allowing the company to ship the vaccine.

“We are very pleased with the results of this inspection,” BioPort spokeswoman Kim Brennen Root said Thursday. The company already has corrected four of the seven problems cited by the FDA, she said.

BioPort has been under pressure to win federal approval to distribute the vaccine, which it has been manufacturing since 1998 but has been unable to ship since failing FDA inspections in 1999 and 2000.

The FDA said Wednesday that BioPort wouldn’t be fully licensed until an inspection of the company where the vaccine is placed into vials was satisfactorily completed early next month.

On Tuesday, the U.S. Department of Health and Human Services announced that up to 10,000 federal employees who might have been exposed to anthrax at the Capitol or postal facilities may get doses of the vaccine to ward off the deadly spores.

In the past, BioPort has supplied the vaccine only to its own employees and the Pentagon. About 500,000 of the 2.4 million troops the Pentagon wanted to inoculate have received the vaccine, but the military’s vaccination program has been put on hold as supplies have run low.

BioPort president Bob Kramer said the corrections required by the FDA are minor compared to problems cited in two earlier inspections, which questioned the sterility of BioPort’s labs but not the safety of the vaccine.

Federal officials stressed that the treatment would be experimental, since the FDA hasn’t approved the vaccine for use after an exposure to anthrax. Previously, it has been taken as a precaution by soldiers and people who work with anthrax.

BioPort spokesman Kim Brennen Root played down the experimental nature of giving the anthrax vaccine after exposure to the spores. The CDC recommended continuing treatment with the vaccine in a December 2000 report, she said.

“This has been thought of before based on studies that do exist,” she said.

Patients being given the option of continued treatment with the anthrax vaccine also are being told they can continue their regimen of antibiotics or end treatment and report any negative symptoms.

Copyright 2001 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Build your health & fitness knowledge

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News